Evgen Pharma PLC Company Profile (LON:EVG)

About Evgen Pharma PLC (LON:EVG)

Evgen Pharma PLC logoEvgen Pharma plc is a clinical-stage drug development company focused on cancer and neurological disease. The Company operates through the segment of development of pharmaceutical products all within the United Kingdom. Its pipeline is based on its Sulforadex technology and includes various synthetic, stabilized analogues of the naturally occurring compound sulforaphane. Its pipeline includes SFX-01: breast cancer; SFX-01: subarachnoid hemorrhage, and other programs. The objective of SFX-01 therapy is to reduce the number of cancer stem cells (CSCs) proliferating in tumors treated with anti-hormonal agents and prolong the duration of response. The objective of SFX-01 therapy (co-administered with standard-of-care nimodipine) is to reduce the vasospasm and incidence of delayed cerebral ischemia in the days following the hemorrhage. It has a preclinical SFX-01 program in multiple sclerosis and a clinical interest in prostate cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:EVG
  • CUSIP: N/A
  • Web: evgen.com/
Capitalization:
  • Market Cap: £13.74 million
  • Outstanding Shares: 73,272,000
Average Prices:
  • 50 Day Moving Avg: GBX 17.51
  • 200 Day Moving Avg: GBX 18.82
  • 52 Week Range: GBX 15.25 - GBX 30.25
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.06 per share
  • Price / Book: 3.13
Profitability:
  • EBITDA: ($3,640,000.00)
  • Return on Equity: -56.78%
  • Return on Assets: -52.02%
Misc:
  • Average Volume: 43,767 shs.
 

Frequently Asked Questions for Evgen Pharma PLC (LON:EVG)

What is Evgen Pharma PLC's stock symbol?

Evgen Pharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "EVG."

Where is Evgen Pharma PLC's stock going? Where will Evgen Pharma PLC's stock price be in 2017?

2 brokers have issued 12 month price objectives for Evgen Pharma PLC's stock. Their forecasts range from GBX 97 to GBX 97. On average, they anticipate Evgen Pharma PLC's stock price to reach GBX 97 in the next year. View Analyst Ratings for Evgen Pharma PLC.

Who are some of Evgen Pharma PLC's key competitors?

Who are Evgen Pharma PLC's key executives?

Evgen Pharma PLC's management team includes the folowing people:

  • Barry Clare, Executive Chairman of the Board
  • Stephen Joseph Franklin, Chief Executive Officer, Executive Director
  • Richard Moulson, Chief Financial Officer, Director
  • Hamina J. Patel, Chief Medical Officer
  • Alan Barge, Non-Executive Director
  • Marc F. D'Abbadie Ph.D., Non-Executive Director
  • Sue Foden Ph.D., Non-Executive Director

How do I buy Evgen Pharma PLC stock?

Shares of Evgen Pharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Evgen Pharma PLC's stock price today?

One share of Evgen Pharma PLC stock can currently be purchased for approximately GBX 18.75.


MarketBeat Community Rating for Evgen Pharma PLC (LON EVG)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  93 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  153
MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Evgen Pharma PLC (LON:EVG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: GBX 97
Consensus Price Target History for Evgen Pharma PLC (LON:EVG)
Price Target History for Evgen Pharma PLC (LON:EVG)
Analysts' Ratings History for Evgen Pharma PLC (LON:EVG)
Show:
DateFirmActionRatingPrice TargetDetails
10/5/2017Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details
10/4/2017Northland SecuritiesReiterated RatingBuyGBX 97View Rating Details
1/4/2016Northland Capital PartnersReiterated RatingBuyGBX 79View Rating Details
(Data available from 10/17/2015 forward)

Earnings

Earnings History for Evgen Pharma PLC (LON:EVG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Evgen Pharma PLC (LON:EVG)
Current Year EPS Consensus Estimate: $4.90 EPS

Dividends

Dividend History for Evgen Pharma PLC (LON:EVG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Evgen Pharma PLC (LON:EVG)
Insider Trades by Quarter for Evgen Pharma PLC (LON:EVG)
Insider Trades by Quarter for Evgen Pharma PLC (LON:EVG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/18/2016Clare,BarryInsiderBuy40,000GBX 22£8,800
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Evgen Pharma PLC (LON:EVG)
Latest Headlines for Evgen Pharma PLC (LON:EVG)
Source:

Social

Social activity is not available for this stock.

Chart

Evgen Pharma PLC (EVG) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.